Painless early
cancer detection

Peekcell is the innovation that enables women’s cancer screening
in the simplest possible way.

It is based on a smart technology that combines the detection of relevant biomarkers found in urine and their analysis with an artificial intelligence algorithm to provide accurate results.

Our mission is to facilitate cancer detection at an early stage

Detected at an early stage, the survival rate for gynaecological cancer is over 90%. However, at an advanced stage, it drops to 20%.

Cancer cases are on the rise

The number of cancer cases is increasing in France and in all occidental countries. Santé Publique France estimates that one in six women will develop cancer during her lifetime (all cancers combined).

Cancers are not largely detected enough

There are three national screening campaigns in France : breast, cervical and colorectal cancers. The participation rates in 2023 are only 59% for cervical cancer and 48% for breast cancer. These rates have been declining over the past 10 years.

Difficulties to access cancer screening

The average time to schedule an appointement for a gynecologist is 2 months and comes with an average travel time of 45 minutes in a rural zone in France.

Women's cancers in France

Based on statistics by Sante Publique France.

70 000

Cancer cases each year

18 000

Deaths each year

€25 Bn

Spent annually by Healthcare Insurance

Our solution

Simple

Based on a urine sample, the test is totally painless and sample collection does not require the intervention of a healthcare professional.

Accessible

Screening is available to women of all ages through their local healthcare professional. Sample shipment is possible

Quick

Our innovative technology and ready-to-use solutions enable quicker processing time from examination to results.

How it works

Step 1: Urine Sample

Collect a urine sample at home or in the laboratory's restroom.

Step 2: Biomarker analysis

Analysis of an early and specific biomarker signature in a biomedical laboratory.

Step 3: Artificial intelligence

A score risk is calculated through an artificial intelligent algorithm to assist the practitioner in decision-making.

Results!

Based on the patient's profile and medical context, the practitionner will refer her for further examinations if cancer is suspected.
Otherwise, the doctor will advise her to continue following national screening recommendations.

About us

Created in 2023 by Hélène, Gwendoline, and Antoine, Peekcell is an innovative French startup based in Paris-Saclay.
We are accompanied by the École Polytechnique incubator X-Up and accelerated by Wilco Healthcare. We are also members of the Réseau Entreprendre Essonne and supported by French Tech Paris-Saclay.